Polymyositis and dermatomyositis laboratory findings: Difference between revisions
| Line 25: | Line 25: | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
*Laboratory findings consistent with the diagnosis of polymyositis and dermatomyositis include:<ref name="pmid29579414">{{cite journal |vauthors=Adler BL, Christopher-Stine L |title=Triggers of inflammatory myopathy: insights into pathogenesis |journal=Discov Med |volume=25 |issue=136 |pages=75–83 |date=February 2018 |pmid=29579414 |doi= |url=}}</ref> | *Laboratory findings consistent with the diagnosis of polymyositis and dermatomyositis include:<ref name="pmid29579414">{{cite journal |vauthors=Adler BL, Christopher-Stine L |title=Triggers of inflammatory myopathy: insights into pathogenesis |journal=Discov Med |volume=25 |issue=136 |pages=75–83 |date=February 2018 |pmid=29579414 |doi= |url=}}</ref> | ||
=== Myositis-specific autoantibodies === | |||
{| class="wikitable" | {| class="wikitable" | ||
!Autoantibody | !Autoantibody | ||
!Effect | !Effect | ||
!Association | |||
!Percentage | !Percentage | ||
! | ! | ||
|- | |- | ||
|Histidyl-tRNA synthetase (anti-Jo-1) | |Histidyl-tRNA synthetase (anti-Jo-1) | ||
| | |||
| | | | ||
| | | | ||
| Line 46: | Line 41: | ||
|- | |- | ||
|Chromodomain helicase DNA binding protein 4 (Mi-2) | |Chromodomain helicase DNA binding protein 4 (Mi-2) | ||
| | |||
| | | | ||
| | | | ||
| Line 51: | Line 47: | ||
|- | |- | ||
|Signal recognition particle (anti-SRP) | |Signal recognition particle (anti-SRP) | ||
| | |||
| | | | ||
| | | | ||
| Line 56: | Line 53: | ||
|- | |- | ||
|Alanyl-tRNA synthetase (PL-12) | |Alanyl-tRNA synthetase (PL-12) | ||
| | |||
| | | | ||
| | | | ||
| Line 61: | Line 59: | ||
|- | |- | ||
|Transcriptional intermediary factor 1-gamma (TIF-1γ) | |Transcriptional intermediary factor 1-gamma (TIF-1γ) | ||
| | |||
| | | | ||
| | | | ||
| Line 66: | Line 65: | ||
|- | |- | ||
|Nuclear matrix protein (NXP-2) | |Nuclear matrix protein (NXP-2) | ||
| | |||
| | | | ||
| | | | ||
| Line 71: | Line 71: | ||
|- | |- | ||
|Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | |Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | ||
| | |||
| | | | ||
| | | | ||
| Line 76: | Line 77: | ||
|- | |- | ||
|Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | |Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | ||
|immune-mediated necrotizing myopathies | |||
|statin-associated necrotizing autoimmune myopathy (SANAM) | |||
|6% | |||
| | | | ||
|- | |||
| | | | ||
| | | | ||
| | | | ||
| Line 85: | Line 88: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| Line 90: | Line 94: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| Line 95: | Line 100: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| Line 100: | Line 106: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
Revision as of 15:53, 5 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
|
Polymyositis and dermatomyositis laboratory findings in the news |
|
Blogs on Polymyositis and dermatomyositis laboratory findings |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Laboratory findings consistent with the diagnosis of polymyositis and dermatomyositis include:[1]
Myositis-specific autoantibodies
| Autoantibody | Effect | Association | Percentage | |
|---|---|---|---|---|
| Histidyl-tRNA synthetase (anti-Jo-1) | ||||
| Chromodomain helicase DNA binding protein 4 (Mi-2) | ||||
| Signal recognition particle (anti-SRP) | ||||
| Alanyl-tRNA synthetase (PL-12) | ||||
| Transcriptional intermediary factor 1-gamma (TIF-1γ) | ||||
| Nuclear matrix protein (NXP-2) | ||||
| Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | ||||
| Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | immune-mediated necrotizing myopathies | statin-associated necrotizing autoimmune myopathy (SANAM) | 6% | |